A hemochromatosis-causing mutation C282Y is a risk factor for proliferative diabetic retinopathy in Caucasians with type 2 diabetes

Journal of Human Genetics

Volumn 48, Issue 12, 2003, Pages 646-649

  Peterlin, Borut ^a   Petrovič, Mojca Globočnik ^a   Makuc, Jana ^a   Hawlina, Marko ^a   Petrovič, Daniel ^b  

^a UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

^b UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

C282Y mutation; Hereditary hemochromatosis; Proliferative diabetic retinopathy; Type 2 diabetes

Indexed keywords

ADULT; AGED; ARTICLE; C282Y GENE; CAUCASIAN; CONTROLLED STUDY; DIABETIC RETINOPATHY; DISEASE ASSOCIATION; FEMALE; GENE; GENE FREQUENCY; GENE MUTATION; HEMOCHROMATOSIS; HETEROZYGOTE; HUMAN; IRON BLOOD LEVEL; IRON METABOLISM; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOGENESIS; RISK FACTOR;

AGED; DIABETES MELLITUS, TYPE 2; DIABETIC RETINOPATHY; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HEMOCHROMATOSIS; HETEROZYGOTE; HUMANS; MALE; MIDDLE AGED; MUTATION; ODDS RATIO; REGRESSION ANALYSIS; RISK FACTORS;

EID: 0346158239     PISSN: 14345161     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10038-003-0094-3     Document Type: Article

References (23)

1. Baynes RD (1996) Assessment of iron status. Clin Biochem 29:209-215
2. Bulaj ZJ, Griffen LM, Jorde LB, Edwards CQ, Kushner JP (1996) Clinical and biochemical abnormalities in people heterozygous for hemochromatosis. N Engl J Med 335:1799-1805
3. Cook JD, Finch CA, Smith NJ (1976) Evaluation of the iron status of a population. Blood 48:449-455
4. Dahl-Jorgensen K, Brinchmann-Hansen O, Hanssen KF, Sandvik L, Aagenaes O (1985) Rapid tightening of blood glucose control leads to transient deterioration of retinopathy in insulin dependent diabetes mellitus: the Oslo study. Br Med J (Clin Res Ed) 290:811-815
5. DeWitt DE, Hirsch IB (2003) Outpatient insulin therapy in type 1 and type 2 diabetes mellitus: scientific review. JAMA 289:2254-2264
6. Feder JN, Gnirke A, Thomas W, Tsuchihashi Z, Ruddy DA, Basava A, Dormishian F, Domingo R Jr, Ellis MC, Fullan A, Hinton LM, Jones NL, Kimmel BE, Kronmal GS, Lauer P, Lee VK, Loeb DB, Mapa FA, McClelland E, Meyer NC, Mintier GA, Moeller N, Moore T, Morikang E, Wolff RK (1996) A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet 13:399-408
7. Feder JN, Tsuchihashi Z, Irrinki A, Lee VK, Mapa FA, Morikang E, Prass CE, Starnes SM, Wolff RK, Parkkila S, Sly WS, Schatzman RC. (1997) The hemochromatosis founder mutation in HLA-H disrupts beta2-microglobulin interaction and cell surface expression. J Biol Chem 272:14025-14028
8. Fernandez-Real JM, Lopez-Bermejo A, Ricart W (2002) Cross-talk between iron metabolism and diabetes. Diabetes 51:2348-2354
9. Fuchs J, Podda M, Packer L, Kaufmann R (2002) Morbidity risk in HFE associated hereditary hemochromatosis C282Y heterozygotes. Toxicology 180:169-181
10. Gardi C, Arezzini B, Fortino V, Comporti M (2002) Effect of iron on collagen synthesis, cell proliferation and MMP-2 expression in rat hepatic stellate cells. Biochem Pharmacol 64:1139-1145
11. Hanson EH, Imperatore G, Burke W (2001) HFE gene and hereditary hemochromatosis: a HuGE review. Human genome epidemiology. Am J Epidemiol 154:193-206
12. Keen H, Lee ET, Russell D, Miki E, Bennett PH, Lu M and the WHO Multinational Group (2001) The appearance of retinopathy and progression to proliferative retinopathy: the WHO multinational study of vascular disease in diabetes. Diabetologia 44 [Suppl 2]:22-30
13. Klein R, Klein BE, Moss SE, Davies MD, De Mets DL (1984) The Wisconsin epidemiologic study of diabetic retinopathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years. Arch Ophthalmol 102:527-532
14. Lebron JA, Bennett MJ, Vaughn DE, Chirino AJ, Snow PM, Mintier GA, Feder JN, Bjorkman PJ (1998) Crystal structure of the hemochromatosis protein HFE and characterization of its interaction with transferrin receptor. Cell 93:111-123
15. Moczulski DK, Grzeszczak W, Gawlik B (2001) Role of hemochromatosis C282Y and H63D mutations in HFE gene in development of type 2 diabetes and diabetic nephropathy. Diabetes Care 24:1187-1191
16. Nankivell BJ, Tay YC, Boadle RA, Harris DC (1994) Lysosomal iron accumulation in diabetic nephropathy. Ren Fail 6:367-381
17. O'Reilly FM, Darby C, Fogarty J, Tormey W, Way EW, Leader M, Murphy GM (1997) Screening of patients with iron overload to identify hemochromatosis and porphyria cutanea tarda. Arch Dermatol 133:1098-1101
18. Parkes JG, Liu Y, Sirna JB, Templeton DM (2000) Changes in gene expression with iron loading and chelation in cardiac myocytes and non-myocytic fibroblasts. J Mol Cell Cardiol 32:233-246
19. Parkkila S, Waheed A, Britton RS, Feder JN, Tsuchihashi Z, Schatzman RC, et al (1997) Immunohistochemistry of HLA-H, the protein defective in patients with hereditary hemochromatosis, reveals unique pattern of expression in gastrointestinal tract. Proc Natl Acad Sci USA 94:2534-2539
20. Porta M, Sjoelie AK, Chatuverdi N, Stevens L, Rottiers R, Veglio M, Fuller JH and the EURODIAB Prospective Complications Study Group (2001) Risk factors for progression to proliferative diabetic retinopathy in the EURODIAB Prospective Complications Study. Diabetologia 44:2203-2209
21. Simonart T, Drgraef C, Stordeur P, Noel JC, Mosselmans R, Van Vooren JP, Parent D, Boelaert JR, Heenen M, Galand P (2001) Iron induces Bcl-2 expression in human dermal microvascular endothelial cells. Free Radic Res 34:221-235
22. Walsh CH, Malins JM (1978) Proliferative retinopathy in a patient with diabetes mellitus and idiopathic haemochromatosis. Br Med J 2:16-17
23. World Health Organization diabetes mellitus: report of a WHO study group (1985) WHO Tech Rep Ser No. 727, pp 9-10